迪瑞医疗收盘上涨1.35%，滚动市盈率114.64倍，总市值41.04亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Dirui Medical, indicating a significant decline in revenue and profit in the latest quarterly report [1][2] - As of August 4, Dirui Medical's stock closed at 15.05 yuan, with a PE ratio of 114.64, marking a new low in 85 days, and a total market capitalization of 4.104 billion yuan [1] - The average PE ratio for the medical device industry is 54.32, with a median of 38.11, positioning Dirui Medical at 107th place within the industry [1][2] Group 2 - Dirui Medical specializes in the research, production, marketing, and service of medical testing instruments and related reagents, with key products including urine analysis, biochemical analysis, and blood cell analysis [1] - The company holds 213 patents, including 136 invention patents and 96 software copyrights [1] - In the first quarter of 2025, Dirui Medical reported revenue of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.6787 million yuan, down 87.13%, with a gross margin of 42.78% [1]